{"nctId":"NCT04345471","briefTitle":"A Study of MD-120 in Patients With Depression","startDateStruct":{"date":"2020-05-18","type":"ACTUAL"},"conditions":["Major Depressive Disorder"],"count":615,"armGroups":[{"label":"MD-120 100 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Desvenlafaxine 100 mg"]},{"label":"MD-120 50 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Desvenlafaxine 50 mg"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Desvenlafaxine 100 mg","otherNames":[]},{"name":"Desvenlafaxine 50 mg","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient with diagnosis of Major Depressive Disorder (MDD) based on the criteria in the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5).\n* Hamilton Depression Rating Scale-17 (HAM-D17) total score of â‰¥20.\n\nExclusion Criteria:\n\n* Patient who meets DSM-5 criteria of the following disorders for current or past history.\n\nSchizophrenia spectrum and other psychotic disorders Bipolar and related disorders Substance use disorders (exclusive of tobacco and caffeine)\n\n* Patient who had suicidal behavior in Columbia-Suicide Severity Rating Scale (C-SSRS) within 1 year before start of screening phase.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Changes in Total MADRS Score From the Baseline to Week 8 Visit During the Treatment Period","description":"Montgomery-Asberg Depression Rating Scale (MADRS) Total Score: Scale ranges from 0 to 60 with a higher score indicating worsening symptoms of depression. Estimates were based on a Mixed-effects Model for Repeated Measures (MMRM) model with the treatment group, assessment timepoint, and the interaction between the treatment group and assessment timepoint as a factor and total MADRS score at baseline as a covariate.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.4","spread":"0.7"},{"groupId":"OG001","value":"-11.1","spread":"0.7"},{"groupId":"OG002","value":"-11.9","spread":"0.7"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Adverse Events (AEs)","description":"An adverse event is any undesirable or unintended sign (including abnormal findings in general laboratory tests, body weight, and standard 12-lead ECG), symptom, or disease in a subject given the investigational drug, irrespective of the causal relationship to the investigational drug.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null},{"groupId":"OG001","value":"117","spread":null},{"groupId":"OG002","value":"124","spread":null}]}]}]},{"type":"SECONDARY","title":"Changes in Total HAM-D17 Score From the Baseline to Week 8 Visit During the Treatment Period","description":"Hamilton Depression Rating Scale-17 (HAM-D17) Total Score: Scale ranges from 0 to 52 with a higher score indicating worsening symptoms of depression. Estimates were based on a MMRM model with the treatment group, assessment timepoint, and the interaction between the treatment group and assessment timepoint as a factor and total HAM-D17 score at baseline as a covariate.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.3","spread":"0.5"},{"groupId":"OG001","value":"-8.4","spread":"0.5"},{"groupId":"OG002","value":"-8.8","spread":"0.5"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Drug Reactions (ADRs)","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Plasma Concentration of Desvenlafaxine","description":null,"paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":204},"commonTop":["Nausea","Somnolence","Dizziness","Nasopharyngitis","Pyrexia"]}}}